Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : Oxysterol
Therapeutic Area : Hepatology (Liver, Pancreatic, Gall Bladder)
Study Phase : Preclinical
Sponsor : MAX BioPharma
Deal Size : Undisclosed
Deal Type : Collaboration
MAX BioPharma and Metaba Announce Collaboration on Metabolomics Studies
Details : The collaboration focuses on developing Oxy210 (oxysterol), a small-molecule antifibrotic, evaluated in preclinical studies for non-alcoholic steatohepatitis and pulmonary fibrosis.
Brand Name : Oxy210
Molecule Type : Small molecule
Upfront Cash : Undisclosed
February 26, 2024
Lead Product(s) : Oxysterol
Therapeutic Area : Hepatology (Liver, Pancreatic, Gall Bladder)
Highest Development Status : Preclinical
Sponsor : MAX BioPharma
Deal Size : Undisclosed
Deal Type : Collaboration
LOOKING FOR A SUPPLIER?